Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis
International Journal of Tuberculosis and Lung Disease, Volume 9, No. 6, Year 2005
Notification
URL copied to clipboard!
Description
SETTING: Globally it is estimated that 273000 new cases of multidrug-resistant tuberculosis (MDR-TB, resistance to isoniazid and rifampicin) occurred in 2000. To address MDR-TB management in the context of the DOTS strategy, the World Health Organization and partners have been promoting an expanded treatment strategy called DOTS-Plus. However, standard definitions for MDR-TB patient registration and treatment outcomes do not exist. OBJECTIVE: To propose a standardized set of case registration groups and treatment outcome definitions for MDR-TB and procedures for conducting cohort analyses under the DOTS-Plus strategy. DESIGN: Using published definitions for drug-susceptible TB as a guide, a 2-year-long series of meetings, conferences, and correspondence was undertaken to review published literature and country-specific program experience, and to develop international agreement. RESULTS: Definitions were designed for MDR-TB patient categorization, smear and culture conversion, and treatment outcomes (cure, treatment completion, death, default, failure, transfer out). Standards for conducting outcome analyses were developed to ensure comparability between programs. CONCLUSION: Optimal management strategies for MDR-TB have not been evaluated in controlled clinical trials. Standardized definitions and cohort analyses will facilitate assessment and comparison of program performance. These data will contribute to the evidence base to inform decision makers on approaches to MDR-TB control. © 2005 The Union.
Authors & Co-Authors
Laserson, Kayla F.
United States, Atlanta
Centers for Disease Control and Prevention
Thorpe, Lorna E.
United States, Atlanta
Centers for Disease Control and Prevention
United States, New York
New York City Department of Health and Mental Hygiene
Leimane, Vaira
Latvia, Riga
State Agency of Tuberculosis and Lung Diseases
Weyer, Karin
South Africa, Tygerberg
South African Medical Research Council
Mitnick, Carole Diane
United States, Boston
Harvard Medical School
Riekstiņa, Vieja
Latvia, Riga
State Agency of Tuberculosis and Lung Diseases
Zarovska, Evija
Latvia, Riga
State Agency of Tuberculosis and Lung Diseases
Rich, Michael Leonard
United States, Boston
Partners in Health
Fraser, Hamish Sf F.
United States, Boston
Partners in Health
Alarcón, E.
Peru, Lima
Natl. Tuberculosis Control Programme
France, Paris
International Union Against Tuberculosis and Lung Disease
Cegielski, J. Peter
United States, Atlanta
Centers for Disease Control and Prevention
Grzemska, Malgorzata
Switzerland, Geneva
Organisation Mondiale de la Santé
Gupta, Rajesh
Switzerland, Geneva
Organisation Mondiale de la Santé
Espinal, Marcos Antonio
Switzerland, Geneva
Organisation Mondiale de la Santé
Statistics
Citations: 14
Authors: 14
Affiliations: 9
Identifiers
ISSN:
10273719
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cohort Study